Joint Inflation With Nominal-pressure and Stability Approach in DES Optimization

Sponsor
Zunyi Medical College (Other)
Overall Status
Recruiting
CT.gov ID
NCT06013007
Collaborator
(none)
130
1
1
25
5.2

Study Details

Study Description

Brief Summary

To achieve the stent optimization following "Keep It Simple and Safe" coronary intervention is recommended. A protocol of Joint Inflation with Nominal-pressure and Stability (JINS) approach in coronary drug-eluting stent (DES) implantation by intracoronary imaging (ICI) guidance could provide additional benefits in reducing unnecessary radiation exposure, and post-dilatation balloon angioplasty-related complications.

Condition or Disease Intervention/Treatment Phase
  • Procedure: ICI-guided JINS approach
N/A

Detailed Description

Variable types of stent inflation protocol to achieve evidence and consensus-based coronary drug-eluting stent (DES) optimization could improve clinical outcomes. The investigators aim to evaluate whether the JINS approach could be adopted in Chinese daily practice.

The investigators will perform ICI (OCT or IVUS)-guided DES implantation in coronary de novo lesions by JINS protocol, described as inflating stent balloon with nominal-pressure (+1~2atm) without decay for at least 30 seconds.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
130 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Eligible patients will be implanted with DES by Joint Inflation with Nominal-pressure and Stability (JINS) approach, which is described as inflating a stent balloon with nominal-pressure without decay for at least 30 seconds.Eligible patients will be implanted with DES by Joint Inflation with Nominal-pressure and Stability (JINS) approach, which is described as inflating a stent balloon with nominal-pressure without decay for at least 30 seconds.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Joint Inflation With Nominal-pressure and Stability Approach in Coronary Drug-Eluting Stent Optimization and Outcomes
Actual Study Start Date :
Aug 22, 2023
Anticipated Primary Completion Date :
Aug 22, 2025
Anticipated Study Completion Date :
Sep 22, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: JINS approach

The JINS approach is described as inflating a stent balloon with nominal-pressure without decay for at least 30 seconds.

Procedure: ICI-guided JINS approach
OCT- or IVUS-guided JINS approach in DES implantation (DES types including Healing-Targeted SUPREME/Infinity Sirolimus-Eluting Stent, GuReater™ Sirolimus-Eluting Stent, XIENCE Alpine Everolimus-Eluting Stent, Promus PREMIER™ Everolimus-Eluting Stent, Resolute Integrity™ Zotarolimus-Eluting Stent, Firebird 2™ Sirolimus-Eluting Stent, Firekingfisher™ Sirolimus-Eluting Stent).

Outcome Measures

Primary Outcome Measures

  1. Stent optimization [At 24 hours]

    To achieve the targets as follow: minimal stent area (MSA) >5.5 mm2 by IVUS or MSA >4.5mm2 by OCT, stent expansion >80% (MSA divided by average reference lumen area), no significant malapposition, no significant stent edge dissection, no significant tissue protrusion, and successful DES implantation without the occurrence of cardiac death, target vessel myocardial infarction, target lesion revascularization, acute stent thrombosis during the first 24 hours after an index procedure.

Secondary Outcome Measures

  1. Target vessel failure [At 12 months]

    Composite of cardiac death, target vessel myocardial infarction, ischaemia-driven target vessel revascularization.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with acute coronary syndrome (UA/NSTEMI/STEMI) plan to undergo OCT- or IVUS-guided DES implantation in de novo lesion.

  • Patients provide written informed consent prior to enrollment.

Exclusion Criteria:
  • Left main, ostial right coronary artery lesion.

  • High thrombus burden at the index primary percutaneous coronary intervention.

  • Active bleeding or bleeding diathesis, thrombocytopenia (platelet <100,000/mL), or hemoglobin <10 g/dL

  • Hepatic dysfunction (serum liver enzyme>3 times the normal limit)

  • Renal failure (eGFR <15 ml/min/1.73m2 or requiring dialysis)

  • Life expectancy < 1 year

Contacts and Locations

Locations

Site City State Country Postal Code
1 Affiliated Hospital of Zunyi Medical University Zunyi Guizhou China 563003

Sponsors and Collaborators

  • Zunyi Medical College

Investigators

  • Principal Investigator: Cai De Jin, MD, Zunyi Medical College

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Cai De Jin, MD, Principal Investigator, Zunyi Medical College
ClinicalTrials.gov Identifier:
NCT06013007
Other Study ID Numbers:
  • JINS
First Posted:
Aug 28, 2023
Last Update Posted:
Aug 28, 2023
Last Verified:
Aug 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Cai De Jin, MD, Principal Investigator, Zunyi Medical College
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 28, 2023